Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3617-3632

  Menne, Stephan ^a   Butler, Scott D ^a   George, Andrea L ^a   Tochkov, Ilia A ^a   Zhu, Yuao ^b   Xiong, Shelly ^b   Gerin, John L ^c   Cote, Paul J ^c   Tennant, Bud C ^a  

^a Department of Obstetrics Gynecology   (United States)

^b GILEAD SCIENCES INC   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; LAMIVUDINE; PLACEBO; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS VIRUS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VIREMIA; VIRUS EXPRESSION; VIRUS HEPATITIS; VIRUS REPLICATION; WOODCHUCK;

ADENINE; ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MARMOTA; PHOSPHONIC ACIDS; RNA, VIRAL; RODENT DISEASES; VIRUS REPLICATION;

EID: 54049115934     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00654-08     Document Type: Article

References (71)

1. Akyildiz, M., F. Gunsar, G. Ersoz, Z. Karasu, T. Ilter, Y. Batur, and U. Akarca. 2007. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig. Dis. Sci. 52:3444-3447.
2. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
3. Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358:718-723.
4. Benhamou, Y., V. Thibault, P. Vig, V. Calvez, A. G. Marcelin, M. H. Fievet, G. Currie, C. G. Chang, L. Biao, S. Xiong, C. Brosgart, and T. Poynard. 2006. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol. 44:62-67.
5. Benhamou, Y., R. Tubiana, and V. Thibault. 2003. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N. Engl. J. Med. 348:177-178.
6. Bessesen, M., D. Ives, L. Condreay, S. Lawrence, and K. E. Sherman. 1999. Chronic active hepatitis B exacerbations in human immunodeficiency virusinfected patients following development of resistance to or withdrawal of lamivudine. Clin. Infect. Dis. 28:1032-1035.
7. Bruno, R., P. Sacchi, C. Zocchetti, V. Ciappina, M. Puoti, and G. Filice. 2003. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 17:783-784.
8. Colonno, R. J., E. V. Genovesi, I. Medina, L. Lamb, S. K. Durham, M. L. Huang, L. Corey, M. Littlejohn, S. Locarnini, B. C. Tennant, B. Rose, and J. M. Clark. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184:1236-1245.
9. Concannon, P., K. Levac, R. Rawson, B. Tennant, and A. Bensadoun. 2001. Seasonal changes in serum leptin, food intake, and body weight in photoentrained woodchucks. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:R951-R959.
10. Concannon, P., P. Roberts, B. Baldwin, and B. Tennant. 1997. Long-term entrainment of circannual reproductive and metabolic cycles by Northern and Southern Hemisphere photoperiods in woodchucks (Marmota monax). Biol. Reprod. 57:1008-1015.
11. Concannon, P. W., V. D. Castracane, R. E. Rawson, and B. C. Tennant. 1999. Circannual changes in free thyroxine, prolactin, testes, and relative food intake in woodchucks, Marmota monax. Am. J. Physiol. 277:R1401-R1409.
12. Cote, P. J., B. E. Korba, R. H. Miller, J. R. Jacob, B. H. Baldwin, W. E. Hornbuckle, R. H. Purcell, B. C. Tennant, and J. L. Gerin. 2000. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 31:190-200.
13. Cote, P. J., C. Roneker, K. Cass, F. Schodel, D. Peterson, B. Tennant, F. De Noronha, and J. Gerin. 1993. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol. 6:161-169.
14. Cullen, J. M., D. H. Li, C. Brown, E. J. Eisenberg, K. C. Cundy, J. Wolfe, J. Toole, and C. Gibbs. 2001. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 45:2740-2745.
15. Cullen, J. M., S. L. Smith, M. G. Davis, S. E. Dunn, C. Botteron, A. Cecchi, D. Linsey, D. Linzey, L. Frick, M. T. Paff, A. Goulding, and K. Biron. 1997. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 41:2076-2082.
16. Dai, C. Y., W. L. Chuang, M. Y. Hsieh, L. P. Lee, J. F. Huang, N. J. Hou, Z. Y. Lin, S. C. Chen, L. Y. Wang, J. F. Tsai, W. Y. Chang, and M. L. Yu. 2007. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antivir. Res. 75:146-151.
17. Delaney, W. E., IV, H. Yang, M. D. Miller, C. S. Gibbs, and S. Xiong. 2004. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob. Agents Chemother. 48:3702-3710.
18. Dore, G. J., D. A. Cooper, A. L. Pozniak, E. DeJesus, L. Zhong, M. D. Miller, B. Lu, and A. K. Cheng. 2004. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189:1185-1192.
19. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, J. Ma, S. Arterburn, S. Xiong, G. Currie, and C. L. Brosgart. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352:2673-2681.
20. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
21. Hoff, J., F. Bani-Sadr, M. Gassin, and F. Raffi. 2001. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin. Infect. Dis. 32:963-969.
22. Hurwitz, S. J., B. C. Tennant, B. E. Korba, J. L. Gerin, and R. F. Schinazi. 1998. Pharmacodynamics of (′)-β-2′,3′- dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrob. Agents Chemother. 42:2804-2809.
23. Hurwitz, S. J., B. C. Tennant, B. E. Korba, I. Liberman, J. L. Gerin, and R. F. Schinazi. 2002. Viral pharmacodynamic model for (-)-beta-2′,3′-dideoxy-5-fluoro-3′-thiacytidine (emtricitabine) in chronically infected woodchucks. Antivir. Chem. Chemother. 13:165-176.
24. Jacob, J. R., B. E. Korba, P. J. Cote, I. Toshkov, W. E. Delaney IV, J. L. Gerin, and B. C. Tennant. 2004. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antivir. Res. 63:115-121.
25. Jain, M. K., L. Comanor, C. White, P. Kipnis, C. Elkin, K. Leung, A. Ocampo, N. Attar, P. Keiser, and W. M. Lee. 2007. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J. Viral Hepat. 14:176-182.
26. Korba, B. E., P. Cote, W. Hornbuckle, R. Schinazi, J. L. Gerin, and B. C. Tennant. 2000. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antivir. Res. 45:19-32.
27. Korba, B. E., P. Cote, W. Hornbuckle, B. C. Tennant, and J. L. Gerin. 2000. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175.
28. Korba, B. E., P. J. Cote, S. Menne, I. Toshkov, B. H. Baldwin, F. V. Wells, B. C. Tennant, and J. L. Gerin. 2004. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir. Ther. 9:937-952.
29. Korba, B. E., R. F. Schinazi, P. Cote, B. C. Tennant, and J. L. Gerin. 2000. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 44:1757-1760.
30. Kuo, A., J. L. Dienstag, and R. T. Chung. 2004. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin. Gastroenterol. Hepatol. 2:266-272.
31. Lacombe, K., J. Gozlan, P. Y. Boelle, L. Serfaty, F. Zoulim, A. J. Valleron, and P. M. Girard. 2005. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19:907-915.
32. Liaw, Y. F. 2001. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir. Chem. Chemother. 12(Suppl. 1):67-71.
33. Lok, A. S., and B. J. McMahon. 2007. Chronic hepatitis B. Hepatology 45:507-539.
34. Marcellin, P., T. Asselah, and N. Boyer. 2005. Treatment of chronic hepatitis B. J. Viral Hepat. 12:333-345.
35. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
36. Mason, W. S., J. Cullen, G. Moraleda, J. Saputelli, C. E. Aldrich, D. S. Miller, B. Tennant, L. Frick, D. Averett, L. D. Condreay, and A. R. Jilbert. 1998. Lamivudine therapy of WHV-infected woodchucks. Virology 245:18-32.
37. Maynard, M., P. Parvaz, S. Durantel, M. Chevallier, P. Chevallier, M. Lot, C. Trepo, and F. Zoulim. 2005. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J. Hepatol. 42:279-281.
38. Menne, S., G. Asif, J. Narayanasamy, S. D. Butler, A. L. George, S. J. Hurwitz, R. F. Schinazi, C. K. Chu, P. J. Cote, J. L. Gerin, and B. C. Tennant. 2007. Antiviral effect of orally administered (-)-β- D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 51:3177-3184.
39. Menne, S., and P. J. Cote. 2007. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J. Gastroenterol. 13:104-124.
40. Menne, S., P. J. Cote, B. E. Korba, S. D. Butler, A. L. George, I. A. Tochkov, W. E. Delaney IV, S. Xiong, J. L. Gerin, and B. C. Tennant. 2005. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 49:2720-2728.
41. Menne, S., C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant, and P. J. Cote. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 76:5305-5314.
42. Nash, K. L., and G. J. Alexander. 2008. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect. Dis. 8:444-448.
43. Nelson, M., S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, G. Matthews, D. Pillay, M. Fisher, M. Bower, and B. Gazzard. 2003. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 17:F7-F10.
44. Nuesch, R., J. Ananworanich, P. Srasuebkul, P. Chetchotisakd, W. Prasithsirikul, W. Klinbuayam, A. Mahanontharit, T. Jupimai, K. Ruxrungtham, and B. Hirschel. 2008. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 22:152-154.
45. Nunez, M., M. Perez-Olmeda, B. Diaz, P. Rios, J. Gonzalez-Lahoz, and V. Soriano. 2002. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 16:2352-2354.
46. Peek, S. F., P. J. Cote, J. R. Jacob, I. A. Toshkov, W. E. Hornbuckle, B. H. Baldwin, F. V. Wells, C. K. Chu, J. L. Gerin, B. C. Tennant, and B. E. Korba. 2001. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl- beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254-266.
47. Peters, M. G., H. W. Hann, P. Martin, E. J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D. F. Gray, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, and C. L. Brosgart. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101.
48. Qi, X., S. Xiong, H. Yang, M. Miller, and W. E. Delaney IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 12:355-362.
49. Rapti, I., E. Dimou, P. Mitsoula, and S. J. Hadziyannis. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313.
50. Ristig, M. B., J. Crippin, J. A. Aberg, W. G. Powderly, M. Lisker-Melman, L. Kessels, and P. Tebas. 2002. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J. Infect. Dis. 186:1844-1847.
51. Schiff, E., C. L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, M. Colombo, H. Tillmann, D. Samuel, S. Zeuzem, J. P. Villeneuve, S. Arterburn, K. Borroto-Esoda, C. Brosgart, and S. Chuck. 2007. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 13:349-360.
52. Seigneres, B., P. Martin, B. Werle, O. Schorr, C. Jamard, L. Rimsky, C. Trepo, and F. Zoulim. 2003. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 47:1842-1852.
53. Sung, J. J., J. Y. Lai, S. Zeuzem, W. C. Chow, E. J. Heathcote, R. P. Perrillo, C. L. Brosgart, M. A. Woessner, S. A. Scott, D. F. Gray, and S. D. Gardner. 2008. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 48:728-735.
54. Tan, J., B. Degertekin, S. N. Wong, M. Husain, K. Oberhelman, and A. S. Lok. 2008. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 48:391-398.
55. Tatti, K. M., B. E. Korba, H. L. Stang, S. Peek, J. L. Gerin, B. C. Tennant, and R. F. Schinazi. 2002. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antivir. Res. 55:141-150.
56. Tennant, B. C. 1999. Animal models of hepatitis B virus infection. Clin. Liver Dis. 3:241-266.
57. Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N. Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. 1998. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191.
58. Tennant, B. C., I. A. Toshkov, S. F. Peek, J. R. Jacob, S. Menne, W. E. Hornbuckle, R. D. Schinazi, B. E. Korba, P. J. Cote, and J. L. Gerin. 2004. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127:S283-S293.
59. Terrault, N. A. 2002. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transpl. 8:S74-S81.
60. Thibault, V., Y. Benhamou, C. Seguret, M. Bochet, C. Katlama, F. Bricaire, P. Opolon, T. Poynard, and H. Agut. 1999. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J. Clin. Microbiol. 37:3013-3016.
61. Van Bommel, F., A. Schernick, U. Hopf, and T. Berg. 2003. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 124:586-587.
62. van Bommel, F., T. Wunsche, S. Mauss, P. Reinke, A. Bergk, D. Schurmann, B. Wiedenmann, and T. Berg. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40:1421-1425.
63. van Bommel, F., T. Wunsche, D. Schurmann, and T. Berg. 2002. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36:507-508.
64. Vryheid, R. E., M. A. Kane, N. Muller, G. C. Schatz, and S. Bezabeh. 2000. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 19:1026-1037.
65. Xiong, X., C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
66. Yang, H., C. E. Westland, W. E. Delaney IV, E. J. Heathcote, V. Ho, J. Fry, C. Brosgart, C. S. Gibbs, M. D. Miller, and S. Xiong. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36:464-473.
67. Ying, C., E. De Clercq, and J. Neyts. 2000. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J. Viral Hepat. 7:79-83.
68. Ying, C., E. De Clercq, W. Nicholson, P. Furman, and J. Neyts. 2000. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral Hepat. 7:161-165.
69. Yokota, T., K. Konno, E. Chonan, S. Mochizuki, K. Kojima, S. Shigeta, and E. de Clercq. 1990. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother. 34:1326-1330.
70. Zhou, T., J. T. Guo, F. A. Nunes, K. L. Molnar-Kimber, J. M. Wilson, C. E. Aldrich, J. Saputelli, S. Litwin, L. D. Condreay, C. Seeger, and W. S. Mason. 2000. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J. Virol. 74:11754-11763.
71. Zhou, T., J. Saputelli, C. E. Aldrich, M. Deslauriers, L. D. Condreay, and W. S. Mason. 1999. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob. Agents Chemother. 43:1947-1954.